The synthesis and evaluation of (E)-styrylisatin analogues as inhibitors of monoamine oxidase B

作者: Van der Walt , Elizna Magdalena

DOI:

关键词: IC50Monoamine oxidase BLead compoundSmall moleculeActive siteChemistryIsatinEnzymeChemical engineeringEnzyme assayStereochemistry

摘要: Monoamine oxidase B (MAO-B) inhibitors are currently clinically used in the symptomatic treatment of Parkinson's disease (PD) and may also possess neuroprotective activity. The irreversible MAO-B inhibitor, (R)-deprenyl, is commonly PD treatment, usually combination with levodopa during dopamine replacement therapy. In contrast reversible inhibition, enzyme recovery after inhibition involves de novo synthesis. relatively quick return activity makes potent safer more desirable. Both isatin caffeine small molecules that have been reported to inhibit MAO-B. Isatin a good endogenous inhibitor (K, = 3 uM) whereas weak (Kj 650 urn). inhibitory potency improved by substitution at C-8 ring styryl side-chain. Addition an electron withdrawing substituent C-3 phenyl produced structures exceptional potency, for example (£)-8-(3-chlorostyryl)caffeine (CSC) 0.1 uM). this study we investigated whether lead compound, isatin, C-5 C-6 will similarly enhance isatin's potency. Preliminary computer modelling proposed (£)-5-styrylisatin (£)-6-styrylisatin analogues, as well into active site recombinant supported hypothesis increased these analogues. sidechain seems be stabilised entrance cavity binding, while moiety located substrate-binding where it involved hydrogen bonding. This duel binding mode similar caffeines thought facilitate caffeines. After successful synthesis compounds were evaluated vitro baboon liver Inhibitory styrylisatin analogues determined spectro photo metric method. potencies all expressed terms concentration compound necessary 50% (IC50 value). Reversibility was confirmed time-dependent showed (E)-styrylisatin independent time period which analogue incubated enzyme. results side-chain on resulted exceptionally potent. For example, (£)-5iv (3-chlorostyryl)isatin 20.7 nM) found 430 times than 8.6 Also, (E)-5-styrylisatin IC50 value 41.7 nM, approximately 210 isatin. moderate, inhibition. has 436.8 nM. electronic lipophilic properties seem important compounds. study, synthesised particular (£)-5-(3chlorostyryl)isatin, potential novel inhibitors. Synthesis evaluatin extensive series styryiisatin would enable Hansch-type structure-activity relationship could identify optimal physicochemical

参考文章(117)
David Blum, Sakina Torch, Nathalie Lambeng, Marie-France Nissou, Alim-Louis Benabid, Rémy Sadoul, Jean-Marc Verna, Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology. ,vol. 65, pp. 135- 172 ,(2001) , 10.1016/S0301-0082(01)00003-X
Jennifer Southgate, G.G.S. Collins, The estimation of monoamine oxidase using 14C-labelled substrates. Biochemical Pharmacology. ,vol. 18, pp. 2285- 2287 ,(1969) , 10.1016/0006-2952(69)90341-4
Geoffrey A. Lyles, Brian A. Callingham, In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues Biochemical Pharmacology. ,vol. 31, pp. 1417- 1424 ,(1982) , 10.1016/0006-2952(82)90037-5
Deidré van den Berg, Kevin R. Zoellner, Modupe O. Ogunrombi, Sarel F. Malan, Gisella Terre’Blanche, Neal Castagnoli Jr., Jacobus J. Bergh, Jacobus P. Petzer, Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorganic & Medicinal Chemistry. ,vol. 15, pp. 3692- 3702 ,(2007) , 10.1016/J.BMC.2007.03.046
Y Sagot, N Toni, D Perrelet, S Lurot, B King, H Rixner, L Mattenberger, P C Waldmeier, A C Kato, An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease British Journal of Pharmacology. ,vol. 131, pp. 721- 728 ,(2000) , 10.1038/SJ.BJP.0703633
H. Neal Bramson, John Corona, Stephen T. Davis, Scott H. Dickerson, Mark Edelstein, Stephen V. Frye, Robert T. Gampe, Phil A. Harris, Anne Hassell, William D. Holmes, Robert N. Hunter, Karen E. Lackey, Brett Lovejoy, Michael J. Luzzio, Val Montana, Warren J. Rocque, David Rusnak, Lisa Shewchuk, James M. Veal, Duncan H. Walker, Lee F. Kuyper, Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. Journal of Medicinal Chemistry. ,vol. 44, pp. 4339- 4358 ,(2001) , 10.1021/JM010117D
Shoulson, Parkinson Study Group, None, Mortality in DATATOP: A Multicenter trial in early Parkinson's disease Annals of Neurology. ,vol. 43, pp. 318- 325 ,(1998) , 10.1002/ANA.410430309
Joaquim F. M. da Silva, Simon J. Garden, Angelo C. Pinto, The chemistry of isatins: a review from 1975 to 1999 Journal of the Brazilian Chemical Society. ,vol. 12, pp. 273- 324 ,(2001) , 10.1590/S0103-50532001000300002